Skip to content

Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure: AUGUST-AHF Cohort Study

Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure: AUGUST-AHF Cohort Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065913
Enrollment
Unknown
Registered
2022-11-18
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

Case series:N/A

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosis of AHF; 2. Age >= 18 years; 3. Voluntarily participate in and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. With major psychiatric disorders or unable to complete follow-up assessment; 2. Known allergies to drugs or drug ingredients; 3. Patients enrolled in other trials within 1 month.

Design outcomes

Primary

MeasureTime frame
90-day all-cause mortality or readmission for heart failure (HF);

Secondary

MeasureTime frame
180-day all-cause death or HF readmission;cardiac-specific death;major cardiovascular adverse event (MACE);length of hospital stay;dyspnoea via visual analogue scale (VAS);dyspnoea via Likert 7-point scale;New York Heart Association (NYHA) cardiac function classification;Minnesota Living with Heart Failure Quality of Life (MLHFQ) scale;Morisky Medication Adherence Scale (MMAS)-8;

Countries

China

Contacts

Public ContactYan Liu

Dongzhimen Hospital, Beijing University of Chinese Medicine

sasliu@yeah.net+86 13811299493

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026